Liver Enzymes' Influence on Hepatic Disorder Diagnosis

Hawraa Hamid  Hussein; Zainab F. Hassan

doi:10.17605/cajmns.v6i3.2804

Hawraa Hamid Hussein Department of Physiology, College of Medicine, University of Babylon, Iraq
Zainab F. Hassan Department of Physiology, College of Medicine, University of Babylon, Iraq

DOI: https://doi.org/10.17605/cajmns.v6i3.2804

Keywords: Prothrombin Time, Risk Stratification, Sensitivity, Alanine Aminotransferase, Lactate Dehydrogenase

Abstract

In order to diagnose and treat liver diseases, liver enzymes are essential. These proteins, known by way of enzymes, aid in the liver's numerous metabolic processes. When liver cells are damaged, these enzymes are released into the bloodstream, which can be detected by blood tests. The levels of liver enzymes can assist reflect the extent of liver damage, the kind of liver disease, and how effectively the liver is functioning. The purpose of the review was to investigate the diagnostic value of Liver Enzymes' in Hepatic Disorder. A thorough analysis of the literature dealing with Liver Enzymes' assays, as well as their clinical effectiveness, sensitivity, specificity, and use in diverse patient populations was performed. The focus of the analysis is on the comparative studies, biomarker performance evaluation, and new diagnostic protocol development. Liver Enzymes' assays enhance the diagnosis of liver diseases by detecting liver enzymes at higher concentrations, which allows for timely intervention and risk stratification. Liver Enzymes' tests have showed considerable challenges like the degree of standardization of the assay. Because it permits more accurate and timely liver disorder notifications, the integration of liver enzymes assays into clinical practice aids in the accurate and timely detection of Liver Enzymes' injury.

References

G. MR и S. J, «Alkaline phosphatase», Cold Spring Harb Protoc, т. 2020, вып. 8, с. 100768, 2020.

Z. MG, F. M, C. DB, и et al, «Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis», JHEP Rep, т. 2, вып. 4, с. 100120, 2020.

P. S и др., «Coagulation profile in liver diseases: A study of 250 cases in a tertiary care hospital», Int J Clin Diagn Pathol, т. 3, вып. 3, сс. 185–188, 2020, doi: 10.33545/pathol.2020.v3.i3c.280.

I. Dolz Pérez и et al, «Development of polypeptide-based therapeutics for topical delivery». 2019 г.

F. H, K. T, F. T, и et al, «Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort study», BMC Gastroenterol, т. 20, вып. 1, сс. 1–9, 2020.

W. S, A. J, D. G, и G. AL, «Marked increase of gamma-glutamyltransferase as an indicator of drug-induced liver injury in patients without conventional diagnostic criteria of acute liver injury», Visc Med, т. 38, вып. 3, сс. 223–228, 2022.

R. F, «Optical immunoassays methods in protein analysis: an overview», Chemosensors, т. 10, с. 326, 2022, doi: 10.3390/chemosensors10080326.

Z. DM, E.-G. MI, O. HA, и et al, «Recent advances with alkaline phosphatase isoenzymes and their inhibitors», Arch Pharm Weinh., т. 353, вып. 5, с. e2000011, 2020.

S. S, P. D, W. R, и et al, «Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments», PLoS One, т. 15, вып. 5, с. e0229753, 2020.

K. HR и H. MA, «Association between serum liver enzymes and metabolic syndrome in Korean adults», Int J Env. Res Public Health, т. 15, с. 1658, 2018.

C. N и др., «The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases», Hepatology, т. 67, сс. 328–357, 2018, doi: 10.1002/hep.29367.

D. AR, I. DK, и J. Z, «Bile metabolism and lithogenesis: an update», Surg Clin, т. 99, вып. 2, сс. 215–229, 2019.

Z. H и др., «Utility of liver function tests in acute cholecystitis», Ann Hepatobiliary Pancreat Surg, т. 23, сс. 219–227, 2019, doi: 10.14701/ahbps.2019.23.3.219.

K. TP, K. V, и P. B, «A study of coagulation profile in diseases of liver: at tertiary care center hospital», Indian J Pathol Oncol, т. 6, вып. 1, сс. 107–111, 2019.

S. T, L. Y, S. J, и et al, «Incidence and etiology of drug-induced liver injury in mainland China», Gastroenterology, т. 156, вып. 8, сс. 2230-2241.e11, 2019.

M. M, P. R, P. V, и et al, «Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease», Aliment Pharmacol Ther, т. 48, сс. 1117–1127, 2018.

K. P и др., «Serum liver enzymes and metabolic syndrome from the Rafsanjan Cohort Study», J Invest Med, т. 71, сс. 140–148, 2023.

S. MG, «The global epidemic of the metabolic syndrome», Curr Hypertens Rep, т. 20, сс. 1–8, 2018.

A. D, G. S, и V.-B. R, «Tissue non-specific alkaline phosphatase and vascular calcification: a potential therapeutic target», Curr Cardiol Rev, т. 15, вып. 2, сс. 91–95, 2019.

T. NA, L. ASF, M. BJ, и et al, «Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance», Hepatology, т. 67, сс. 1560–1599, 2018.